Melanotan 2 Questions, Answered

This page consolidates the most common questions about Melanotan 2 (MT-2) and answers each from what published peer-reviewed literature, regulatory statements, and supplier product documentation actually report. Melanotan 2 is a synthetic cyclic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that is sold and studied as a research chemical for research use only — it is not an approved medicine in the United States or the European Union, and it is not intended for human or veterinary consumption. The sections below cover its structure and mechanism, what pigmentation and tanning studies have described, the non-pigmentary effects reported in the literature, how it differs from Melanotan 1 (afamelanotide) and PT-141 (bremelanotide), its legal and regulatory standing, what documentation says about reconstitution and storage in a laboratory, and where the evidence base is genuinely thin.

What Melanotan 2 is, chemically

Melanotan 2 is a cyclic lactam heptapeptide analogue of α-MSH, developed in the late 1980s at the University of Arizona during medicinal-chemistry work on melanocortin peptides. Native α-MSH is a 13-amino-acid linear peptide cleaved from proopiomelanocortin (POMC). Researchers identified the His-Phe-Arg-Trp core as the message sequence responsible for receptor recognition, then truncated the molecule and closed it into a ring through a lactam bridge. Two substitutions are central to the design: D-phenylalanine in place of L-phenylalanine at the position corresponding to Phe7, and norleucine replacing methionine.

Those changes matter for a simple reason described throughout the peptide literature: native α-MSH is degraded rapidly by serum peptidases and has a very short circulating half-life, measured in minutes. Cyclization constrains the peptide into a conformation closer to the receptor-bound shape, and the D-amino acid substitution resists enzymatic cleavage. The practical result reported in pharmacology papers is a compound that is both more metabolically stable and more potent at melanocortin receptors than the endogenous hormone it mimics — which is why comparisons in the literature typically describe MT-2 as far more potent than α-MSH rather than merely equivalent.

Because the message core is preserved rather than made selective, Melanotan 2 binds several melanocortin receptor subtypes. This is the origin of the term researchers apply to it: a non-selective melanocortin receptor agonist.

What research reports about the mechanism of action

The primary described mechanism is agonism at melanocortin receptors, with pigmentation effects attributed chiefly to the melanocortin-1 receptor (MC1R) on epidermal melanocytes. MC1R is a G-protein-coupled receptor. When an agonist occupies it, the receptor couples to Gαs, stimulating adenylate cyclase and raising intracellular cyclic AMP. Elevated cAMP activates protein kinase A, which phosphorylates CREB and drives transcription of microphthalmia-associated transcription factor (MITF). MITF in turn upregulates the enzymatic machinery of melanin synthesis — tyrosinase, TYRP1, and DCT — inside melanosomes.

The downstream consequence described in pigment-cell biology is a shift in melanin output. MC1R signalling favours production of eumelanin, the brown-black, more photoprotective pigment, over red-yellow pheomelanin. Newly synthesised melanosomes are then transferred from melanocytes to surrounding keratinocytes, where the pigment is distributed through the epidermis as those cells migrate outward.

Critically, this pathway is downstream of, not dependent on, ultraviolet light. Under normal physiology, UV exposure damages keratinocyte DNA, stabilises p53, and increases POMC transcription, so keratinocytes release α-MSH that acts on neighbouring melanocytes. A synthetic MC1R agonist engages the receptor directly and bypasses that UV-initiated upstream step. This is the mechanistic reason literature and product documentation describe pigmentation changes occurring in the absence of UV exposure — the melanogenic switch is being flipped at the receptor rather than by photodamage. Several published reports nonetheless note that UV exposure and MC1R agonism can act additively on observed pigment intensity, and that response varies widely between individuals with different baseline MC1R genotypes and constitutive pigmentation.

What research reports about pigmentation and tanning studies

Published human studies of Melanotan 2 are small, early-phase, and mostly decades old, but they consistently report increases in measured skin melanin density. The foundational trials in the 1990s, conducted at the University of Arizona, administered the peptide to small cohorts of volunteers and used reflectance spectrophotometry and visual assessment to document darkening, including in subjects with limited or no UV exposure. Sample sizes in the single digits to low tens were typical; these were proof-of-mechanism investigations, not efficacy or safety programmes.

What pigmentation researchers derive from this work is a usable model system rather than a finished therapy. MC1R agonism gives investigators a way to stimulate eumelanogenesis pharmacologically, which is useful for studying melanocyte biology, the photoprotective role of eumelanin, MC1R polymorphisms and red-hair variants, and pigment-transfer dynamics. Much of the current pigmentation literature on melanocortins uses cultured human melanocytes, melanoma cell lines, or animal models rather than human subjects, because in vitro systems permit controlled measurement of tyrosinase activity and MITF expression.

The related but distinct clinical story belongs to Melanotan 1, not Melanotan 2. Melanotan 1 — afamelanotide — was developed into a regulated implant studied and authorised in some jurisdictions for erythropoietic protoporphyria, a rare light-sensitivity disorder. That programme demonstrates the therapeutic interest in the melanocortin pathway, but it is a different molecule with a different regulatory history, and findings from it should not be transferred to Melanotan 2.

Honest framing matters here: there is no large, modern, controlled body of evidence characterising Melanotan 2's pigmentary effects, durability, or long-term consequences in humans. Reported observations of darkening are real in the literature; robust dose-response and safety characterisation is absent.

What research reports about effects beyond pigmentation

Pigmentation is only one of several documented actions, because Melanotan 2 activates multiple melanocortin subtypes rather than MC1R alone. Reported receptor interactions span MC1R, MC3R, MC4R, and MC5R, with MC2R (the adrenal ACTH receptor) largely spared. Each subtype maps to a different physiology described in the melanocortin literature:

• MC3R and MC4R — expressed in the hypothalamus and other central nervous system regions, and central to the melanocortin system's regulation of energy balance. MC4R agonism is one of the best-established anorexigenic signals in neuroendocrinology; loss-of-function MC4R mutations are among the most common monogenic causes of human obesity, and MC4R agonists have been pursued as metabolic drug candidates. This receptor pharmacology is the reason Melanotan 2 appears in appetite and energy-homeostasis research, and why reduced food intake and lower body weight are reported in rodent studies. The mechanism described is central appetite suppression and, in some animal work, effects on insulin sensitivity and energy expenditure — not a direct fat-burning action on adipose tissue.
• MC4R and sexual function — melanocortin signalling in the spinal cord and hypothalamus influences erectile and arousal pathways. Effects of this kind were noted in early Melanotan 2 human studies and became the basis for a separate development programme.
• MC5R — associated with exocrine gland function, including sebaceous secretion, in animal literature.
• Vascular and pigment-cell effects — flushing and transient blood-pressure or heart-rate changes have been described in early-phase reports, along with darkening of existing naevi and freckles, which is consistent with melanocytic stimulation in already pigmented lesions.

Reports of nausea, facial flushing, spontaneous erections in male subjects, and appetite loss recur across the early human literature and in case reports gathered by poison centres and dermatology clinics. Case-report literature has additionally described melanocytic lesion changes and, in isolated instances, melanoma diagnosed in unregulated users — causality cannot be established from case reports, but researchers cite them as a reason the pigmentary and melanocytic consequences remain an open question.

How Melanotan 2 compares with Melanotan 1 and PT-141

The clearest distinction is selectivity. Melanotan 1 (afamelanotide) is a linear 13-amino-acid α-MSH analogue with a single amino-acid substitution pattern that keeps it relatively focused on MC1R-mediated pigmentation, with a short half-life managed in its regulated form by a slow-release implant. Melanotan 2 is a shortened, cyclised peptide that acts across MC1R, MC3R, MC4R, and MC5R. That breadth explains both the wider effect profile reported for MT-2 — appetite, sexual-function, and autonomic effects alongside pigmentation — and the greater difficulty of interpreting its findings, since multiple receptor systems are engaged at once.

PT-141, or bremelanotide, is the connective tissue between the two stories. It is a metabolite-derived analogue of Melanotan 2: the C-terminal amide of MT-2 is replaced with a hydroxyl group, yielding a compound with substantially reduced pigmentary activity but retained central melanocortin activity relevant to sexual arousal. Bremelanotide was developed through formal clinical programmes and approved in the United States for hypoactive sexual desire disorder in premenopausal women under a brand name. In other words, the sexual-function observations made incidentally during early Melanotan 2 pigmentation work were deliberately isolated and turned into a separate, regulated drug — while Melanotan 2 itself never completed that path.

What is known about legal and regulatory status in the US

Melanotan 2 is not an approved drug in the United States and cannot lawfully be marketed as a medicine, dietary supplement, or cosmetic. It has never completed the investigational and approval process required for human use, so no legal pathway exists for selling it for tanning, weight management, or any other human purpose. Regulators have acted on this repeatedly: the FDA has issued warning letters to sellers making human-use claims, and agencies in other countries — including the UK's MHRA, Australia's TGA, and several EU member-state authorities — have issued public consumer warnings and enforcement notices about unlicensed melanotan products.

Several specific points recur in questions about its status:

• It is not a controlled substance. Melanotan 2 is not scheduled under the US Controlled Substances Act, so simple possession is not a drug-scheduling offence. Its unlawfulness arises from food-and-drug law — unapproved new drug and misbranding provisions — rather than narcotics law. Being unscheduled is not the same as being permitted.
• Prescribing is not a workaround. Because there is no approved Melanotan 2 product, a clinician has no approved formulation to prescribe. Bremelanotide is a separate, approved molecule; afamelanotide is separately regulated. Neither authorisation extends to Melanotan 2.
• The research-chemical channel is why it remains available. Suppliers distribute Melanotan 2 labelled strictly for laboratory research, not for human consumption, which is the basis on which it is sold. Purchases made under that framing carry the corresponding restriction: the material is intended for in vitro and controlled laboratory investigation by qualified researchers, and no human-use guidance accompanies it.
• Imported and grey-market material is a documented quality problem. Published analyses of melanotan products obtained outside regulated supply chains have found inconsistent peptide content and identity, and regulators cite sterility and contamination concerns. Peer-reviewed identity and purity testing — typically HPLC and mass spectrometry — is the only meaningful check, which is why third-party certificates of analysis are standard documentation requests in laboratory procurement.
• Anti-doping status. Melanocortin analogues of this kind are also treated as prohibited non-approved substances under anti-doping rules covering agents without current regulatory approval for human therapeutic use.

What documentation says about form, handling, and stability

Research-grade Melanotan 2 is supplied as a lyophilised (freeze-dried) white powder in sealed vials, most commonly at 10 mg per vial. Product documentation and general peptide-stability literature describe several handling points that laboratories follow to preserve integrity:

• Lyophilised powder is the stable form. Sealed, protected from light and moisture, and held at refrigerated or frozen temperatures, the dry peptide is described as stable for extended periods — often cited in supplier documentation as months to years at −20 °C. Brief exposure to ambient temperature during shipping is generally tolerated by lyophilised peptides.
• Reconstitution shortens the stability window. Bacteriostatic water or sterile water is the usual diluent described in laboratory protocols. Once in solution, the peptide is markedly less stable; refrigeration at 2–8 °C is standard, and solutions are typically treated as usable for a matter of weeks rather than months.
• Physical handling affects potency. Diluent is directed down the vial wall rather than jetted onto the powder, and vials are swirled gently instead of shaken, because agitation and foaming promote aggregation and denaturation of peptides. Repeated freeze–thaw cycling of reconstituted material is avoided for the same reason; aliquoting is the usual mitigation.
• Light and pH matter. Amber vials or light-protected storage are common, and the tryptophan and other oxidation-prone residues in melanocortin peptides make prolonged exposure to light, heat, and oxygen a documented degradation route.

On oral administration: melanocortin peptides of this class have negligible oral bioavailability. Gastric acid and intestinal proteases degrade the peptide, and its size and polarity limit intestinal absorption, so the compound is not orally active in any meaningful sense. Research work is conducted parenterally in animal models or directly on cell cultures. Nasal formulations have circulated in grey markets, and regulators have specifically warned about them; absorption from such products is poorly characterised.

Pricing for research-grade material is a frequent question. Publicly listed prices from research-peptide suppliers for a 10 mg vial commonly fall in the range of roughly 20 to 60 US dollars, varying with purity documentation, quantity, and supplier. Because identity and purity vary substantially across the market, documentation quality rather than price is what published analyses treat as the meaningful differentiator.

Where the evidence is thin

The honest summary is that Melanotan 2's mechanism is well characterised while its human profile is not. Melanocortin receptor pharmacology, cAMP/PKA/MITF signalling, and eumelanin synthesis are thoroughly documented in pigment-cell biology. MC4R's role in appetite regulation is one of the most robust findings in metabolic neuroscience. What does not exist for Melanotan 2 specifically is a modern controlled clinical dataset: no large trials, no established dose-response relationships in humans, no long-term follow-up, and no systematic characterisation of effects on melanocytic lesions. The human data that exist come from small early-phase studies and from case reports describing unregulated use — a literature useful for hypothesis generation and hazard signalling, not for conclusions about outcomes.

For that reason, published discussion of Melanotan 2 consistently separates two things: the melanocortin pathway, which is a legitimate and active area of drug discovery that has already produced approved molecules, and Melanotan 2 itself, which remains an unapproved investigational peptide restricted to laboratory research. Research plans involving it are designed and reviewed accordingly, with institutional oversight, and never on the basis of human-use protocols.